Dr. Patricia L. Kropf on Decitabine and Arsenic Trioxide in AML and MDS
December 10th 2015Patricia L. Kropf, MD, discusses a combination of decitabine and arsenic trioxide as a replacement for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who cannot withstand induction chemotherapy.